Albert Bourla, DVM, PhD, Pfizer’s chief executive officer, announced during the company’s third quarter 2019 earnings call that Pfizer has set launch dates for its biosimilar rituximab, Ruxience (referencing Rituxan), and trastuzumab, Trazimera (referencing Herceptin).
Albert Bourla, DVM, PhD, Pfizer’s chief executive officer, announced during the company’s third quarter 2019 earnings call that Pfizer has set launch dates for its biosimilar rituximab, Ruxience (referencing Rituxan), and trastuzumab, Trazimera (referencing Herceptin).
According to Bourla, Ruxience will become commercially available in January 2020, and Trazimera will follow on February 15, 2020. The company previously confirmed that it plans to launch its biosimilar bevacizumab, Zirabev, on December 31, 2019.
Ruxience was approved in July of this year for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis. Trazimera was approved in March of this year for the treatment of HER2-positive breast cancer and metastatic gastric cancer. Zirabev was approved in June of this year for the treatment of metastatic colorectal cancer, non—small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and cervical cancer.
During his comments, Bourla also noted that Pfizer’s efforts to encourage biosimilar-friendly policies and legislation are beginning to bear fruit. “None of our breakthroughs will do any good if patients cannot afford them,” said Bourla, adding that “our proposals regarding biosimilars have been well received,” and bipartisan legislation to promote biosimilars in the United States is advancing.
Bourla indicated that key objectives for Pfizer products in general include reducing patients’ out-of-pocket costs, and aggressively pursing value-based reimbursement that will link reimbursement with outcomes.
In terms of Pfizer’s existing biosimilars business, biosimilar infliximab, Inflectra, which treats inflammatory diseases, saw 8% growth in the United States over 2018, rising from $71 million to $77 million (unaudited). Worldwide, however, sales of the same product, sold as Remsima in other territories, were down by 7%, falling from $166 million in 2018 to $155 million (unaudited).
Biosimilar epoetin alfa, Retacrit, brought in $64 million worldwide, and $42 million in the United States.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Sustainable Biosimilar Markets Achieve Widespread Market Uptake Through Collective Action
April 22nd 2024Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that applying collective action theory can achieve widespread biosimilar market uptake by fostering collaboration for long-term benefits.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.